Julio Delgado
Overview
Explore the profile of Julio Delgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
221
Citations
5165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2025 Feb;
:102026.
PMID: 39987917
No abstract available.
2.
Albarran-Fernandez V, Angelats L, Delgado J, Gros A, Urbano-Ispizua A, Guedan S, et al.
Nat Commun
. 2025 Jan;
16(1):1144.
PMID: 39880825
No abstract available.
3.
Chapaprieta V, Maiques-Diaz A, Nadeu F, Clot G, Massoni-Badosa R, Mozas P, et al.
Blood
. 2025 Jan;
PMID: 39841466
Previous studies have reported that chronic lymphocytic leukemia (CLL) shows a de novo chromatin activation pattern as compared to normal B cells. Here, we explored whether the level of chromatin...
4.
Medina A, Muntanola A, Crespo M, Ramirez A, Hernandez-Rivas J, Abrisqueta P, et al.
Med Clin (Barc)
. 2025 Jan;
PMID: 39799061
Introduction: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries, with a median age at diagnosis of 72 years. This guide, developed by...
5.
Gomez-Puerta J, Monegal A, Ponce A, Peris P, Martinez-Cibrian N, Sarmiento-Monroy J, et al.
Semin Arthritis Rheum
. 2025 Jan;
71:152610.
PMID: 39754918
Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment for hematological malignancies. However, its association with immune-related complications such as rheumatic complications, is not well defined....
6.
Pineyroa J, Lopez-Oreja I, Nadeu F, Martinez-Farran A, Arostegui J, Lopez-Guerra M, et al.
Cells
. 2024 Nov;
13(22).
PMID: 39594588
The presence of a monoclonal protein detected by serum immunofixation electrophoresis (sIFE) has been reported as an adverse prognostic factor in chronic lymphocytic leukemia (CLL). However, the genetic underpinning of...
7.
Bachiller M, Barcelo-Genestar N, Rodriguez-Garcia A, Alserawan L, Dobano-Lopez C, Gimenez-Alejandre M, et al.
Mol Ther
. 2024 Nov;
33(1):317-335.
PMID: 39563035
CD19 CAR-T therapy has achieved remarkable responses in relapsed/refractory non-Hodgkin lymphoma (NHL). However, challenges persist, with refractory responses or relapses after CAR-T administration linked to CD19 loss or downregulation. Given...
8.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado J, Bataller A, Ortiz-Maldonado V, Benitez-Ribas D, et al.
Cell Rep Med
. 2024 Oct;
5(11):101803.
PMID: 39471818
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell...
9.
Arguello-Tomas M, Mozas P, Albiol N, Lopez-Esteban M, Sierra J, Nomdedeu J, et al.
Cancer
. 2024 Sep;
131(1):e35552.
PMID: 39264834
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However,...
10.
El Maimouni C, Daca-Alvarez M, Delgado J, Pellise M, Balaguer F
Gastroenterol Hepatol
. 2024 Aug;
48(3):502239.
PMID: 39214338
No abstract available.